Loading
RTOG 9601 showed that adding two years of hormone therapy to salvage radiotherapy after prostate surgery lengthens survival, mainly in men with higher PSA levels at relapse.
RTOG 9601 randomised 760 men with a rising PSA after radical prostatectomy to salvage radiotherapy (64.8 Gy) with 24 months of bicalutamide 150 mg or placebo. Twelve-year overall survival was 76.3 percent with bicalutamide and 71.3 percent with placebo (hazard ratio 0.77), with fewer prostate cancer deaths and metastases; the benefit was concentrated in men with PSA above 0.7 ng/mL, and gynaecomastia was common (Shipley and colleagues, New England Journal of Medicine 2017).
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
760 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 12 yearsprimary | Salvage radiotherapy plus bicalutamide | 384 | 76.3% | - | - | - |
| Salvage radiotherapy plus placebo | 376 | 71.3% |
Shares NRG Oncology, IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares NRG Oncology, IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tag radiation-wave4.
Shares NRG Oncology, IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.